Determination of IL33, IL32 and TNF concentrations in Hepatitis C Patients and Possible of Co-infection with Toxoplasma

Abstract

Background: Hepatitis C virus (HCV) and toxoplasma co-occurrence is an uncommon but potentially significant disease. The parasitic infection known as toxoplasmosis is brought on by the Toxoplasma gondii microbe, whereas HCV is a viral infection known for its ability to damage the liver. When both infections are present simultaneously, the symptoms and complications can be more severe compared to each infection individually.

Goals: The purpose of this research is to diagnose co-infection between toxoplasmosis and hepatitis C and Analyse and compare the serum concentrations of tumour necrosis factor (α) (IL-32 and IL-33). healthy non-infected people and patients with co-infections (HCV and toxoplasmosis).

Methods: 150 people—100 with the Hepatitis C virus and 50 healthy as a control group—are involved. The patients' and the control group's Tumour, Serum levels of necrosis factor-α, IL-32, and IL-33 were assessed.

Results: The results showed the level of Toxo -IgM and Toxo IgG high level in patients compared with control group. IL-32, IL-33 levels also was high in the patients who had co infection, HCV than control group. TNF-α also in high level in co infection patients.

Conclusion: According the results we concluded that a very effective impact on IL-32, IL-33, and the quantities of interleukins (IFNα) in patient serum, as well as the prevalence of co-infection is approximately 20% among HCV patients. The findings show that, in comparison to the healthy control group, those who had co-infection (HCV and toxoplasmosis) had increased TNF-α, IL-32, and IL-33 levels.

Recommendation: Additional research ought to explore the time-dependent changes in these biomarkers and assess their viability as focal points for individualized treatment strategies.